1. Leukemia. 2018 Jan;32(1):30-37. doi: 10.1038/leu.2017.200. Epub 2017 Jun 23.

DNMT3A mutant transcript levels persist in remission and do not predict outcome 
in patients with acute myeloid leukemia.

Gaidzik VI(1), Weber D(1), Paschka P(1), Kaumanns A(1), Krieger S(1), 
Corbacioglu A(1), Krönke J(1), Kapp-Schwoerer S(1), Krämer D(2), Horst HA(3), 
Schmidt-Wolf I(4), Held G(5), Kündgen A(6), Ringhoffer M(7), Götze K(8), Kindler 
T(9), Fiedler W(10), Wattad M(11), Schlenk RF(1), Bullinger L(1), Teleanu V(1), 
Schlegelberger B(12), Thol F(12), Heuser M(12), Ganser A(12), Döhner H(1), 
Döhner K(1); German-Austrian Acute Myeloid Leukemia Study Group (AMLSG).

Author information:
(1)Universitätsklinikum Ulm, Ulm, Germany.
(2)Klinikum Oldenburg, Oldenburg, Germany.
(3)Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany.
(4)Universitätsklinikum Bonn, Bonn, Germany.
(5)Universitätsklinikum des Saarlandes, Homburg, Germany.
(6)Universitätsklinikum Düsseldorf, Düsseldorf, Germany.
(7)Städtisches Klinikum Karlsruhe GmbH, Karlsruhe, Germany.
(8)Klinikum rechts der Isar der Technischen Universität München, München, 
Germany.
(9)Universitätsmedizin Mainz, Mainz, Germany.
(10)Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
(11)Kliniken Essen Süd, Ev. Krankenhaus Essen-Werden gGmbH, Essen, Germany.
(12)Medizinische Hochschule Hannover, Hannover, Germany.

We investigated the prognostic impact of minimal residual disease (MRD) 
monitoring in acute myeloid leukemia patients harboring DNA methyltransferase 
3A-R882H/-R882C mutations (DNMT3Amut). MRD was determined by real-time 
quantitative PCR (RQ-PCR) in 1494 samples of 181 DNMT3Amut patients. At the time 
of diagnosis, DNMT3Amut transcript levels did not correlate with presenting 
clinical characteristics and concurrent gene mutations as well as the survival 
end points. In Cox regression analyses, bone marrow (BM) DNMT3Amut transcript 
levels (log10-transformed continuous variable) were not associated with the rate 
of relapse or death. DNMT3Amut transcript levels were significantly higher in BM 
than in blood after induction I (P=0.01), induction II (P=0.05), consolidation I 
(P=0.004) and consolidation II (P=0.008). With regard to the clinically relevant 
MRD time points, after two cycles of induction and at the end of therapy, 
DNMT3Amut transcript levels had no impact on the end point remission duration 
and overall survival. Of note, only a minority of the patients achieved RQ-PCR 
negativity, whereas most had constantly high DNMT3Amut transcript levels, a 
finding which is consistent with the persistence of clonal hematopoiesis in 
hematological remission.

DOI: 10.1038/leu.2017.200
PMID: 28643785 [Indexed for MEDLINE]